Inotropic agents. Synthesis and structure-activity relationships of new milrinone related cAMP PDE III inhibitors
- PMID: 9507660
Inotropic agents. Synthesis and structure-activity relationships of new milrinone related cAMP PDE III inhibitors
Abstract
The synthesis of 6-substituted 5-acyl-1,2-dihydro-2-oxo-3-pyridinecarbonitriles 1b,c, 1,2,5,6,7,8-hexahydro-2,5-dioxo-3-quinolinecarbonitriles 1d-g and esters of 5-cyano-1,6-dihydro-2-methyl-6-oxo-3-pyridinecarboxylic acid 2b-e is described. In the case of 1e and 1f, a careful elucidation of the reaction mechanism is discussed. As milrinone analogues, the above compounds were tested on contractile activity and frequency rate of spontaneously beating atria from reserpine-treated guinea pigs. The methyl and the benzyl esters 2b and 2e showed an appreciable positive inotropic activity when compared to milrinone. A fitting study with the DISCO (Distance Comparison) model has been carried out on 2e. This modeling approach allowed for the improvement of the pharmacophoric requirements for a better interaction with the cAMP-specific PDE (PDE III), thought to be the final biological target of these cardiotonic agents.
Similar articles
-
New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):109-18. doi: 10.1007/s00210-002-0675-2. Epub 2003 Jan 23. Naunyn Schmiedebergs Arch Pharmacol. 2003. PMID: 12595951
-
Synthesis and cardiotonic activity of 2-substituted 5-cyano-1,6-dihydro-6-oxo-3-pyridinecarboxylic acids and their methyl or ethyl esters.Farmaco. 1992 Apr;47(4):427-37. Farmaco. 1992. PMID: 1388591
-
Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.Arzneimittelforschung. 1988 Sep;38(9):1293-8. Arzneimittelforschung. 1988. PMID: 2852013
-
[Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].Nihon Rinsho. 2007 May 28;65 Suppl 5:43-8. Nihon Rinsho. 2007. PMID: 17571364 Review. Japanese. No abstract available.
-
Studies on the mechanism of action of the bipyridine milrinone on the heart.Basic Res Cardiol. 1989;84 Suppl 1:85-103. doi: 10.1007/BF02650349. Basic Res Cardiol. 1989. PMID: 2554875 Review.
Cited by
-
Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.Bioorg Chem. 2020 Jul;100:103880. doi: 10.1016/j.bioorg.2020.103880. Epub 2020 Apr 28. Bioorg Chem. 2020. PMID: 32388428 Free PMC article.
-
New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):109-18. doi: 10.1007/s00210-002-0675-2. Epub 2003 Jan 23. Naunyn Schmiedebergs Arch Pharmacol. 2003. PMID: 12595951
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials